-
结直肠癌是消化道常见的恶性肿瘤, 虽然近年来在结直肠癌的诊断和治疗方面取得了一些进展, 在一定程度上提高了患者生存率, 但总体预后仍不满意。肝转移是结直肠癌患者死亡的主要原因, 40%~50%的结直肠癌患者最终会发生肝转移[1-2]。随着检查手段的进步、手术及围手术期处理水平的提高, 结直肠癌肝转移患者若得到合适的手术治疗, 生存率将明显提高; 患者是否适合手术, 首先依赖于影像学检查提供的准确信息[3-4]。对于结直肠癌肝转移患者, 以往多采用癌胚抗原水平、超声、CT、MRI和结直肠镜等进行术前检测和术后随访, 尽管已采取这些措施, 但由于结直肠癌肝转移灶的隐匿性和常规影像学检查的局限性, 许多患者失去了手术切除和长期生存的机会, 甚至在术中意外发现转移灶而不得不改变治疗方案, 导致不少患者接受了无意义的手术治疗。PET-CT能够发现全身转移灶, 是一种近年来逐渐广泛应用于临床和科研的新型影像学技术, 本文就18F-FDGPET-CT在结直肠癌肝转移诊治中应用的最新进展作一综述。
PET-CT在结直肠癌肝转移诊治中的应用进展
Progress in application of PET-CT in diagnosis and therapy of liver metastasis from colorectal cancer
-
摘要: 用葡萄糖类似物18F-FDG作为显像剂的PET-CT是一种无创性显像方法,它在肿瘤尤其是转移性结直肠癌的诊断、分期、再分期、疗效监测和随访中有非常重要的作用。PET-CT融合显像将功能显像和解剖显像结合在一起,提高了全身肿瘤显像的敏感性和特异性,明显优于单独PET或CT。目前,PET-CT在结直肠癌肝转移中的应用主要是检测和甄别肝脏转移性病灶、制定治疗方案和进行疗效评价。
-
关键词:
- 结直肠肿瘤 /
- 正电子发射断层显像术 /
- 体层摄影术, X线计算机 /
- 肝转移
Abstract: PET-CT using 18F-FDG is a non-invasive imaging modality which has been recognized as the most important imaging modality in diagnosing, staging, restaging, therapy monitoring and follow-up of cancer patients, especially in metastatic colorectal cancer.PET-CT combines functional and anatomical imaging to improve sensitivity and specificity of whole-body imaging and provides incremental diagnostic value over PET or CT alone.Nowadays, applications of PET-CT imaging in liver metastasis from colorectal cancer mainly included detection and differentiation of malignant and benign liver lesions, determination of appropriate therapeutic strategies and evaluation of treatments. -
[1] Gallagher D, Kemeny N. Treatment of patients with colorectal cancer: emphasis on liver metastases. Expert Opini Pharmacother, 2009, 10(1): 109-124. doi: 10.1517/14656560802631301 [2] Jovine E, Biolchini F, Talarico F, et al. Major hepatectomy in patients with synchronous colorectal liver metastases: whether or not a contraindication to simultaneous colorectal and liver resection?. Colorectal Dis, 2007, 9(3): 245-252. doi: 10.1111/j.1463-1318.2006.01152.x [3] Tsutsui M, Yoshino S, Sakamoto K, et al. Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleu?ral metastasis. Gan To Kagaku Ryoho, 2009, 36(12): 2351-2353. [4] Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging, 2010, 31(1): 19-31. doi: 10.1002/jmri.22010 [5] Finkelstein SE, Fernandez FG, Dehdashti F, et al. Unique site-and time-specific patterns ofrecurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg, 2008, 15(5): 483-487. doi: 10.1007/s00534-007-1237-2 [6] Tan MC, Castaldo ET, Gao F, et al. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [ 18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg, 2008, 206(5): 857-868. doi: 10.1016/j.jamcollsurg.2007.12.023 [7] Vriens D, de Geus-Oei LF, van Laarhoven HW, et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nucl Med Commun, 2009, 30(7): 550-557. doi: 10.1097/MNM.0b013e32832bdc80 [8] Liu HY, Teramoto K, Kawamura K, et al. Evaluation of tumor growth in vivo in a rat model of liver metastasis, using a newly devised index ob tained by positron emission tomography with [18F]FDG. J Hepatobiliary Pancreat Surg, 2007, 14(3): 276-282. doi: 10.1007/s00534-006-1133-1 [9] Bamba Y, Itabashi M, Tada Y, et al. Roles of positron emission tomography/computed tomography (PET/CT) in the management of colorectal cancer. Gan To Kagaku Ryoho, 2009, 36(13): 2521-2525. [10] Garcea G, Ong SL, Maddern GJ. The currentrole of PET-CT in the characterization of hepatobiliary malignancies. HPB(Oxford), 2009, 11(1): 4-17. [11] Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol, 2009, 32(6): 1179-1186. doi: 10.1007/s00270-009-9658-8 [12] Roth ES, Fetzer DT, Barron BJ, et al. Does colon cancer ever metastasize to bone first?a temporal analysis of colorectal cancer progression. BMC Cancer, 2009, 9: 274. doi: 10.1186/1471-2407-9-274 [13] Paschos KA, Bird N. Currentdiagnostic and therapeutic approaches for colorectal cancer liver metastasis. Hippokratia, 2008, 12(3): 132-138. [14] Grassetto G, Fornasiero A, Bonciarelli G, et al. Additional value of FDG-PET/CT in management of"solitary"liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol, 2010, 12(2): 139-144. doi: 10.1007/s11307-009-0249-5 [15] Orlacchio A, Schillaci O, Fusco N, et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med, 2009, 114(4): 571-585. doi: 10.1007/s11547-009-0393-7 [16] Harada K, Kato J, Takemoto K, et al. Case of smallearly cancer of sigmoid colon, which recurred with liver metastasis 18 months after surgical resection. Nippon Shokakibyo Gakkai Zasshi, 2009, 106(5): 660-667. [17] Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with(18)F-FDG PET: a randomized study. J Nucl Med, 2009, 50(7): 1036-1041. doi: 10.2967/jnumed.109.063040 [18] Pawlik TM, Assumpcao L, Vossen JA, et al. Trends in non-therapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol, 2009, 16(2): 371-378. doi: 10.1245/s10434-008-0230-6 [19] D'souza MM, Sharma R, Mondal A, et al. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases. Nucl Med Commun, 2009, 30(2): 117-125. doi: 10.1097/MNM.0b013e32831ec57b [20] Cantwell CP, Setty BN, Holalkere N, et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison oflow radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr, 2008, 32(5): 738-744. doi: 10.1097/RCT.0b013e3181591d33 [21] Badiee S, Franc BL, Webb EM, et al. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol, 2008, 191(5): 1436-1439. doi: 10.2214/AJR.07.3750 [22] Liu YN, Huang MX, An Q, et al. The impact of PET/CT on therapeutic strategy of patients with colorectal cancer metastasis. Hepatogastroenterology, 2009, 56(93): 968-970. [23] Soyka JD, Veit-Haibach P, Strobel K, et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med, 2008, 49(3): 354-361. doi: 10.2967/jnumed.107.048249 [24] Dirisamer A, Halpern BS, Schima W, et al. Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol, 2008, 10(6): 335-340. doi: 10.1007/s11307-008-0159-y [25] Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol, 2009, 99(2): 93-98. doi: 10.1002/jso.21207 [26] Adie S, Yip C, Chu F, et al. Resection ofliver metastases from colorectal cancer: does preoperative chemotherapy affectthe accuracy of PET in preoperative planning?. ANZ J Surg, 2009, 79(5): 358-361. [27] Goshen E, Davidson T, Zwas ST, et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat, 2006, 5(1): 37-43. doi: 10.1177/153303460600500105 [28] Melton GB, Lavely WC, Jacene HA, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg, 2007, 11(8): 961-969. doi: 10.1007/s11605-007-0170-7 [29] Travaini LL, TrifiròG, Ravasi L, et al. Role of [ 18F]FDG-PET/CT after radiofrequency ablation of liver metastases: pre-liminar y results. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1316-1322. doi: 10.1007/s00259-008-0748-7 [30] Werner MK, Brechtel K, Beyer T, et al. PET/CT for the assessment and quantification of (90)Y biodistribution after selective internal radiotherapy(SIRT) of liver metastases. Eur J Nucl Med Mol Imaging, 2010, 37(2): 407-408. doi: 10.1007/s00259-009-1317-4 [31] Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol, 2008, 67(2): 362-371. doi: 10.1016/j.ejrad.2007.11.017
计量
- 文章访问数: 2009
- HTML全文浏览量: 738
- PDF下载量: 2